Introduction: Diffuse large B-cell lymphoma (DLBCL) is one of the most prevalent subtypes of non-Hodgkin lymphoma (NHL), characterized by aggressive clinical behavior and high mortality rates in the absence of early treatment. Globally, NHL accounts for approximately 4% of all cancers, with an estimated incidence of 7.5 per 100,000 individuals per year. In Brazil, the incidence rate is 9.1 per 100,000, with DLBCL comprising approximately 30–35% of cases. This context underscores the importance of regional analyses to inform public health policies and early diagnostic strategies. Objective: To analyze mortality due to DLBCL in the Northern Region of Brazil from January 1, 2019, to December 31, 2023, by year of occurrence, sex, age group, and federative unit. Methods: This is a descriptive, retrospective epidemiological study using data from the Mortality Information System (SIM), accessed via the TABNET/DATASUS platform. Records coded as ICD-10 C83.3 were included from all seven states in the Northern Region (Acre, Amapá, Amazonas, Pará, Rondônia, Roraima, and Tocantins) for the period between 2019 and 2023. Variables analyzed included year of death, sex, age group (<20; 20–39; 40–59; ?60 years), and state. Absolute number of deaths and crude mortality rates per 100,000 population were calculated based on IBGE population estimates for 2023. Linear regression was applied to assess temporal trends, and the chi-square test was used to compare rates among states. Results: A total of 1,203 deaths from DLBCL were recorded in the Northern Region during the study period, with an average annual increase of 3.2%. The state of Pará accounted for 38% of deaths (n?=?457), followed by Amazonas (22%; n?=?265); the remaining states contributed between 5% and 10% (n?=?60–120). There was a predominance of male deaths (male-to-female ratio of 1.4:1) and a higher occurrence among individuals aged 60 years and older (72%; n?=?866). Crude mortality rates ranged from 1.8 to 4.5 per 100,000 inhabitants, with the highest rates in Pará (4.5) and the lowest in Roraima (1.8). Based on place of residence, Pará showed a significant annual increase of 5.1% (p?Conclusion: Mortality from DLBCL in Northern Brazil increased between 2019 and 2023, particularly in more populous states and among the elderly. The findings underscore the need to strengthen epidemiological surveillance, promote early diagnosis, and expand access to treatment. Additionally, investigating socioeconomic and structural factors affecting disease management is essential to inform more effective public health policies.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
